Genmab A/S (GMAB) Stock: Price, Forecast & Analyst Target
Genmab A/S (GMAB) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $50.97 (-1.91%), as of the Nov 18, 2026 trading session; market cap $31.4B.
Educational signal · not a buy or sell recommendation · How to read this
Genmab A/S · GMAB · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Genmab develops antibody medicines through a portfolio that already includes commercialized cancer and serious-disease therapies, partnered clinical programs, and proprietary development platforms. Its latest revenue and profit rebound now has to prove durable while the balance sheet carries substantially more debt than cash.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Genmab A/S (GMAB)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 6 of the last 8 reports
- Altman Z 21.04 · Piotroski F 5
- ROE 12.3% · ROA 5.6% · current ratio 2.45 · earnings yield 2.3% · free-cash-flow yield 2.6%
Holding back: soft growth
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 69 | Strong | |
| 69 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 72 | Strong | |
| 72 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $50.97 | |
| Change on the day | -1.91% | |
| 52-week range | $23.62–$59.97 | |
| Market capitalisation | $31.4B | — |
| Price / earnings (trailing) | 43.33 | |
| Shares traded on the day | 2.96M | |
| Beta (volatility vs the S&P 500) | 0.65 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Genmab A/S (GMAB): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Genmab A/S (GMAB), and what does it report?
Short answer · as of
Genmab discovers and develops antibody therapies.
Research dated 2026-09-12.
Darzalex, teprotumumab, ofatumumab, amivantamab, and tisotumab vedotin sit in its commercialized portfolio, while epcoritamab and other candidates extend the business through collaborations and clinical development.
The reported revenue, gross profit, operating profit, and research spending are company-level outcomes from this blended model. Genmab is therefore not merely a biotechnology pipeline awaiting commercialization: marketed medicines and extensive research activity coexist inside the same business.
What do the latest results show for Genmab A/S (GMAB)?
Research dated 2026-09-12.
Revenue rebounded in the latest reported period, while gross profit, operating profit, net income, and diluted earnings all improved from the preceding period. Research and administrative spending also rose, but the additional gross profit more than absorbed those increases.
Reported earnings and revenue exceeded expectations after consecutive disappointments. Management has set a full-year revenue range; that guidance describes the intended destination, while the latest results provide the first evidence of renewed operating momentum.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.02B | $401M | $0.65 (diluted) |
| Q4 FY2025 | $1.06B | $31M | — |
| Q1 FY2026 | $896M | $53M | $0.08 (diluted) |
| Q2 FY2026 | $1.16B | $303M | $0.49 (diluted) |
What are the financial strengths and risks for Genmab A/S (GMAB)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Genmab remains profitable, and every period in the available cash-flow series produced positive operating cash flow. Annual results also show that substantial research investment has coexisted with net income, while liquidity ratios and the distress screen do not indicate immediate pressure from current obligations.
The harder balance-sheet issue is the gap between cash and debt. Cash and investments have fallen sharply across the reported window, operating cash generation has been uneven, and debt now exceeds available cash by a wide margin. That combination makes the direction of cash as important as reported operating profit.
What should you watch next at Genmab A/S (GMAB)?
Short answer · as of
Current published price targets run low $40.00 · high $70.00 · consensus $50.83 · median $47.50 against a quoted price of $50.97 (as of Nov 18, 2026).
Research dated 2026-09-12.
Watch whether revenue sustains its latest rebound, whether operating profit keeps expanding despite higher research and administrative spending, and whether operating cash flow strengthens from subdued recent levels. Stabilization in cash relative to debt would make the accounting recovery more convincing.
The scheduled earnings release will also test progress toward management’s full-year revenue range. Longer-horizon analyst estimates anticipate continued revenue growth but span increasingly varied outcomes, placing commercial execution and pipeline conversion at the center of what follows.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Genmab A/S compare with its peers?
Short answer
Genmab A/S's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Genmab combines marketed antibody medicines, proprietary antibody formats, partnered programs, and a sizable internal organization. That is a different operating shape from a research-stage antibody developer whose value depends mainly on clinical candidates.
It also differs from a conventional commercial drugmaker because research remains a major expense and collaborations with AbbVie, Seagen, CureVac, BioNTech, Janssen, and Novo Nordisk extend development across counterparties. The resulting business has several routes to value creation, but its outcomes depend on partner execution and clinical progress as well as demand for commercialized medicines.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| Genmab A/S (GMAB) — this page | $50.97 | $31.4B | 72 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $40.00 – $70.00
- Consensus target
- $50.83
- Median target
- $47.50
Consensus record · Captured .
Measured against a quoted price of $50.97 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GMAB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GMAB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Genmab A/S (GMAB)?
What Investors Ask About Genmab A/S (GMAB) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Darzalex important to Genmab?
Darzalex is a commercialized human monoclonal antibody used in multiple myeloma, other blood cancers, and amyloidosis. Its presence helps make Genmab an operating medicines business rather than solely a collection of experimental programs.
How does AbbVie fit into Genmab’s epcoritamab program?
AbbVie is Genmab’s development partner for epcoritamab, which is being pursued in relapsed or refractory lymphoma and chronic lymphocytic leukemia. The arrangement places a prominent pipeline asset inside a collaborative development model.
Why do DuoBody and HexaBody matter to Genmab?
DuoBody and HexaBody candidates appear across solid-tumor and hematologic programs. Their use throughout the pipeline shows how Genmab applies its antibody-development formats across distinct disease targets rather than tying research to a lone medicine.
Why can Genmab’s cash balance fall while operations generate cash?
Operating cash flow remained positive across the reported periods, yet cash and short-term investments declined sharply. Operating cash flow captures only part of total cash movement, so the balance can fall even when the core cash-flow measure stays positive.
What is the GMAB stock price today?
The last price recorded for Genmab A/S (GMAB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GMAB price target?
The analyst consensus price target for Genmab A/S (GMAB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com